Genomic Health — Merger or Acquisition (July 2019)
9 slides from Genomic Health's merger presentation, Jul 31, 2019
Slide 1: Creating a high-growth leader to detect cancer earlier and improve how it is treated
2 Creating a high-growth leader to detect cancer earlier and improve how it is treated Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing platform for growth Forms best-in-class commercial, R&D and clinical organization Provides global infrastructure to a
Slide 2: Joins two of the strongest brands in cancer diagnostics
© © © © Joins two of the strongest brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing platform for growth Forms best-in-class commercial, R&D and clinical organization Provides global infrastructure to accelerate availability of new innovative cancer diagnostics to patients Enhance
Slide 3: Q2 2019 Financial Results
Q2 2019 Financial Results Brad Cole CFO
Slide 4: Genomic Health Reports 19% Revenue Growth and Record Profit in 2nd Quarter 2019
Genomic Health Reports 19% Revenue Growth and Record Profit in 2nd Quarter 2019 Raises Full-Year Guidance 5 Increased worldwide revenue by 19.4% to $114.1M driven by strength across entire business with 1st half revenue growth of: 13% in U.S. invasive breast cancer 44% in U.S. early-stage prostate c
Slide 5: Q2 2019 Tests & Revenue vs. Q2 2018
Q2 2019 Tests & Revenue vs. Q2 2018 Revenue – US Oncology +13% led by US IBC, Urology +74% led by US Prostate & Int’l +28% led by Breast; +19% YOY, driven by Volume +$13.7M, and ASP +$4.9M
Slide 6: Profit & Loss Statement: Q2'19 Actual vs. Q2'18 Actual
Profit & Loss Statement: Q2’19 Actual vs. Q2’18 Actual Net Income up 2X; Double Digit Top Line Growth at 19%; ~45% Incr Operating Leverage OPEX: R&D: $1.8M 26 incremental HC and $0.8M consulting to support Portal work offset by no $2.6M Biocartis milestone payment in Q2’19 Commercial US: Increased H
Slide 7: International Update
International Update Torsten Hoof Chief International Business Officer
Slide 8: International Update
International Update Torsten Hoof Chief International Business Officer Genomic Health’
Slide 9: Cautionary Statement
* * * Cautionary Statement This presentation contains statements, including statements regarding the proposed acquisition of Genomic Health, Inc. (“Genomic Health”) by Exact Sciences Corporation (“Exact Sciences”) that are forward-looking statements within the meaning of Section 27A of the Securitie